首页> Cancer genetics> Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement.

Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement.

导出 LinkOut

翻译打印收藏纠错

第一作者： Somprakash,Dhangar

第一单位： ICMR - National Institute of Immunohaematology, 13th floor, New multistoried building, K.E.M Hospital campus, Parel, Mumbai, 400012, India.

作者： Somprakash,Dhangar ^[1] ; Chandrakala,Shanmukhaiah ^[2] ; Leena,Sawant ^[1] ; Jagdeeshwar,Ghatanatti ^[1] ; Aditi,Shah ^[2] ; Leo Prince,Mathan S ^[2] ; Babu Rao,Vundinti ^[3]

作者单位： ICMR - National Institute of Immunohaematology, 13th floor, New multistoried building, K.E.M Hospital campus, Parel, Mumbai, 400012, India. ^[1] Department of clinical Haematology, King Edward Memorial Hospital, Mumbai, Maharashtra, India. ^[2] ICMR - National Institute of Immunohaematology, 13th floor, New multistoried building, K.E.M Hospital campus, Parel, Mumbai, 400012, India.. Electronic address: vbaburao@hotmail.com. ^[3]

关键词 Azacitidine BCR-FGFR1 rearrangement Haematological remission Sorafenib aCML miCyR

医学主题词人类(Humans);阿扎胞苷(Azacitidine);易位, 遗传(Translocation, Genetic);骨髓增殖性疾病(Myeloproliferative Disorders);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);受体, 成纤维细胞生长因子, 1型(Receptor, Fibroblast Growth Factor, Type 1)

DOI 10.1016/j.cancergen.2023.03.004

PMID 36965231

发布时间 2023-06-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交